892 / 1224
/
/
SBRT for prostate cancer
Matthias Guckenberger - DEGRO 2015
3
Why SBRT
Why not SBRT
Small well circumscribed target
Risk of extracapsular extension
Low alpha / beta ratio
Really very low
Benefit of dose escalation
Only for bRFS
Technical solutions available
Lack of standardization
Strong competition
Should not be a reason per se
13.06.2016